Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... BRIDGEWATER, N.J. , Oct. 2, 2014 /PRNewswire/ ... in synthetic biology, and Amneal Pharmaceuticals LLC ... volume in the U.S., today announced the formation ... a target active pharmaceutical ingredient (API).  Utilizing Intrexon,s ... collaboration is to develop a consistent, scalable, and ...
(Date:10/1/2014)...  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ... of high pressure-based sample preparation systems to the life ... to present at the 2 nd  Global Life ... The Conference will take place at the Warsaw Stock ... Schumacher , President and CEO of PBI, will present ...
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Slone ... Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, reported ... positions at the director level and above from July ... to stay on top of rapid breakthroughs in diagnostics, ... many diagnostic companies have been forced to fold, consolidate, ...
Breaking Biology Technology:Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2
... $15 million milestone payment, WILMINGTON, N.C., Feb. ... Takeda Pharmaceutical Company Limited,s new drug,application (NDA) for ... of type 2 diabetes, has been accepted for ... partnered with Takeda to develop the,compound., Under ...
... Kelly Named New Controller --, MADISON, N.J., Feb. 28 ... John C. Kelly to Vice President and,Controller, Wyeth, effective March ... after a 30-year career at Wyeth, including serving,as Vice President ... Wyeth in 2002, Mr. Kelly has handled a wide range ...
... LLC,( http://www.gene2drug.com ) -- the leading market research ... announces the publication of its,latest report, "Conferences & ... at scientific conferences and trade shows are an ... on investment (ROI),remains elusive for most vendors. This ...
Cached Biology Technology:PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2Wyeth Announces Executive Change in Finance Organization 2BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market 2BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... used by bodybuilders could be the key to treating ... new research shows. The amino acid L-tyrosine had ... in laboratory tests on mice, significantly improving symptoms of ... New South Wales (UNSW) found. Trials showed that ...
... The EpiGen Consortium, an international alliance of the ... Sciences of the Agency for Science, Technology and ... Southampton, Medical Research Council Lifecourse Epidemiology Unit, ... announce the creation of a research collaboration with ...
... 22, 2011 /PRNewswire-iReach/ -- Researchers have demonstrated ... Curran eat significantly more fruits and vegetables and get ... 12 months ago.  By participating in the WellSteps ... in nutrition, physical activity, and sleep quality. Employees also ...
Cached Biology News:Hope for muscle wasting disease 2EpiGen announces collaboration with Nestlé 2New Study Shows Impact of Employee Wellness Efforts 2
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: